Cardiol Therapeutics Inc.

TSX:CRDL.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$1.36 +0.67%

+$0.00 today

Market cap
$164.10M
Beta
0.48
P/E (TTM)
-4.5
EPS (TTM)
-$0.33
52W Low $1.23High $2.33

Volume 0.08M

Average 0.12M

CRDL.TO Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Cardiol Therapeutics Inc.TSX: CRDL.TO

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow turns positive

Q1 FY2026 financing cash flow was CA$13.6M, compared with -CA$13.84K a year earlier. Trailing-twelve-month financing cash flow was CA$29.15M.

Context

  • Financing cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly financing cash flow holds near CA$13.6M or moves back toward the trailing-twelve-month quarterly average of CA$7.29M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$13.6M-12.5% QoQ
Last fiscal yearDec 2025
CA$15.54M-17.5% YoY
LTMMar 2026
CA$29.15M+55.5% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+98335.9%——
1 year-17.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

CAD · from the cash flow

Latest · FY2025
15.54M CAD
Year-over-year change
-17.5%
4-year CAGR
-36.1%

Financing Cash Flow vs competitors

How CRDL.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +55.5% is the highest of 2, against a peer median of -1.0%.
CRDL.TO Competitors
Financing Cash Flow for CRDL.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MSCL.TOSatellos Bioscience Inc.LTM Mar 2026$53.29M USD—-6.3%—
CRDL.TOCardiol Therapeutics Inc.LTM Mar 2026CA$29.15M CAD+55.5%——
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$23.36M USD-1.0%+44.1%41.9%
Peer median (excluding CRDL.TO) —-1.0%+18.9%41.9%

Competitors are the stored peer set for CRDL.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(31.64M)(30.93M)(28.13M)(36.68M)(33.82M)
Depreciation & Amortization220.42K219.91K248.36K373.11K101.98K
Deferred Income Tax(4.92M)0(1.59M)00
Stock-Based Compensation8.5M5.01M4.17M14.28M10.7M
Change in Working Capital76.52K5.75M746.8K(931.57K)(733.34K)
Accounts Receivables(59.95K)(144.18K)67.18K(81.75K)135.43K
Inventory17.97K(4.47M)000
Accounts Payables2.39M4.47M(1.29M)(1.06M)263.69K
Other Working Capital(2.27M)5.89M679.62K214.93K(1.13M)
Other Non-Cash Items4.21M(7.27M)(627.28K)(2.1M)(105.34K)
Operating Cash Flow(23.55M)(27.22M)(25.18K)(25.06M)(23.85M)
Capital Expenditures(12.92K)(74.71K)(64)(21.29K)(24.48K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00(64.25K)00
Investing Cash Flow(12.92K)(74.71K)(64.31K)(21.29K)(24.48K)
Debt Repayment(51.92K)(53.93K)(55.38K)(41.53K)(55.38K)
Common Stock Issued84.08M0021.36M16.07M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities9.35M0(55.38K)(2.47M)(477.03K)
Financing Cash Flow93.44M(53.93K)(55.38K)18.84M15.54M
Effect of Forex Changes(11.13K)2.92M762.04K1.89M(824.04K)
Net Change in Cash69.87M(24.43M)(24.54M)(4.35M)(9.16M)
Free Cash Flow(23.56M)(27.3M)(25.24K)(25.08M)(23.88M)

Cardiol Therapeutics Inc.

TSX:CRDL.TO

Intrinsic Alpha fair value

Locked

Current Price

$1.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.